Details

Autor(en) / Beteiligte

• Kanold, Justyna
• Paillard, Catherine
• Tchirkov, Andrei
• Lang, Peter
• Kelly, Antony
• Halle, Pascale
• Isfan, Florentina
• Merlin, Etienne
• Marabelle, Aurelien
• Rochette, Emmanuelle
• Deméocq, François

Titel

NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

Ist Teil von

• Pediatric blood & cancer, 2012-10, Vol.59 (4), p.739-742

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo‐HSCT) performed for the high‐risk neuroblastoma (NB). We describe a 6‐year‐old male with refractory NB who relapsed 22 months after haplo‐HSCT. A complete remission was obtained with a combination of immuno‐chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo‐graft provided via haplo‐NK cells and the immunogenic platform that haplo‐HSCT offers for future treatment. Our post‐relapse strategy shows that chemo‐ and bio‐treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739–742. © 2011 Wiley Periodicals, Inc.